CLINICAL ROLE -
Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD
Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.
Read More
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Clinical Efficacy of Non-Statin Treatment Options in ASCVD
Focusing on PCSK9 inhibitors, inclisiran, and bempedoic acid, the panel compares treatment efficacy and outlines patient factors that influence treatment decisions.
Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD
Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.
Key Barriers in Implementing Guideline-Directed Cholesterol Treatment
Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.
Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines
The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.
Stroke and TIAs- Minimizing the Risk of Recurrence
Pharmacists can help reduce the number of recurrent strokes by counseling patients on the importance of adhering to their medication regimens and educating them about modifiable risk factors.
